FUND III$1.3B closed · $3.1B raised to date

Extraordinarycontinues here.

TCGX is a science-driven investment firm backing visionary entrepreneurs who turn scientific breakthroughs into transformative medicines.

Explore our portfolio Our approach

Partnering with companies redefining medicine

00By the numbers

Committed capital and conviction behind the next generation of medicines.

$0B

Capital raised across three funds

Portfolio companies

World-class science partners

Offices: Palo Alto · SF · NYC

01Our mission

We support private and public companies building the future of medicine, translating cutting-edge science into products that make a meaningful difference for patients.

02How we invest

Built for the long arc of drug development.

Breakthrough medicines take time, talent and conviction. Everything about TCGX — our network, our people and our fund structure — is designed around that reality.

01 — SCIENCE

Great science, improving human health

We find companies with the potential to do great things and aim to be valuable partners to those intrepid innovators.

02 — NETWORK

Drug development is a team sport

Scientific advisors, operating executives and Nobel and Lasker laureates guide our team and our companies.

03 — CAPITAL

Patient capital

Closed-end funds mean no redemption pressure, so we can commit to companies for the long term.

04 — CROSSOVER

Any stage, private to public

We provide capital across a company's lifecycle and help portfolio companies diligence pipelines, navigate the capital markets and expand globally across North America, Europe and Asia.

03Portfolio

Backing the companies redefining medicine.

View full portfolio

04Science network

Guided by the scientists who defined their fields.

Our Science Partners include Nobel Prize and Lasker Award recipients. Their expertise is an invaluable resource for our team and our portfolio companies.

Nobel Prize recipientsLasker Award recipientsHHMI investigators

Meet our Science Partners